Castle Biosciences
Provides clinician-facing molecular diagnostic tests across dermatology and gastroenterology.
Something off on this page? Send us feedback.
Profile
Develops and commercializes molecular diagnostic tests for dermatologic cancers, Barrett’s esophagus, uveal melanoma, and atopic dermatitis. Its portfolio grew from dermatologic testing through internal development and targeted acquisitions.
Develops and commercializes molecular diagnostic tests that help clinicians manage dermatologic cancers, Barrett’s esophagus, uveal melanoma, and atopic dermatitis. DecisionDx-Melanoma is a core gene-expression test, alongside DecisionDx-SCC, DecisionDx-UM, MyPath Melanoma, TissueCypher, and limited-access AdvanceAD-Tx.
The portfolio began in dermatologic molecular diagnostics and expanded through internal development and targeted acquisitions. Its original franchise was dermatologic molecular diagnostics. The company remains led by its founder. It serves clinician-facing dermatology and gastroenterology settings.
Revenue depends on laboratory operations, clinician adoption, and third-party payer reimbursement, including Medicare coverage. Medicare coverage for DecisionDx-SCC was discontinued.
Company facts
Categories
Key statistics
Year to date −13.2% · Average volume (30d) 476.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 3, 2026 | BTIG | Reiterate | Buy | $50 | $44 |
| Jul 31, 2026 | Robert W. Baird | Target | $37 | $36 | |
| Jun 24, 2026 | Roth Capital | Initiate | Buy | $40 | |
| May 29, 2026 | KeyBanc | Target | $50 | $35 | |
| Apr 20, 2026 | Canaccord Genuity | Reiterate | Buy | $50 | $40 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | −$0.41 | −$0.07 | +82.8% | $86.2M | $103.5M | +20.1% | +4.52% |
| May 6, 2026Q1 FY26 | −$0.49 | −$0.49 | 0.0% | $79.2M | $84.2M | +6.3% | −22.26% |
| Feb 26, 2026Q4 FY25 | −$0.23 | −$0.08 | +65.2% | $79.9M | $87.0M | +8.9% | −7.25% |
| Nov 3, 2025Q3 FY25 | −$0.34 | −$0.02 | +94.1% | $80.4M | $83.0M | +3.3% | +21.70% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $88.0M | $86.2M | $83.0M | $87.0M | $83.7M | $103.5M | |
| Gross profit | $71.6M | $68.6M | $64.3M | $68.7M | $63.1M | $79.8M | |
| Operating income | −$27.9M | −$4.3M | −$6.8M | −$3.8M | −$18.4M | −$3.1M | |
| Net income | −$25.8M | $4.5M | −$501.0K | −$2.3M | −$14.5M | −$2.1M | |
| Diluted EPS | −$0.90 | $0.15 | −$0.02 | −$0.08 | −$0.49 | −$0.07 | |
| Gross margin | 81.4% | 79.5% | 77.5% | 79.0% | 75.5% | 77.1% | |
| Operating margin | -31.7% | -4.9% | -8.2% | -4.4% | -22.0% | -3.0% |
Fiscal years (4-quarter sums)FY21 $94.1M · FY22 $137.0M · FY23 $219.8M · FY24 $332.1M · FY25 $344.2M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $266.8M · Total debt $36.7M · Total assets $561.2M · Shareholders' equity $470.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 30.55M · Float 26.99M · 88.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.29M | 10.78% | 13F | Aug 7, 2026 |
| RTW Investments, LP | 2.78M | 9.09% | 13F | Aug 14, 2026 |
| Principal Financial Group Inc | 1.73M | 5.65% | 13F | Aug 4, 2026 |
| Vanguard Capital Management LLC | 1.23M | 4.01% | 13F | Aug 13, 2026 |
| Acadian Asset Management LLC | 918.7K | 3.01% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Tobin W. Juvenal | officer: Chief Commercial Officer | −9,050 | $35.04 |
| Aug 25, 2026 | Kristen M. Oelschlager | officer: Chief Operating Officer | −12,384 | $34.42 |
| Aug 24, 2026 | Kristen M. Oelschlager | officer: Chief Operating Officer | −12,218 | $33.69 |
| Aug 17, 2026 | Tobin W. Juvenal | officer: Chief Commercial Officer | −1,730 | $29.59 |
| Aug 14, 2026 | Derek J. Maetzold | director, officer: Pres. & Chief Exec. Officer | −6,398 | $30.02 |
Peers
- Quest Diagnostics
Melanoma nodal-risk testing sold through a national diagnostics network
- Tempus AI
Melanoma molecular-risk testing commercialized through an oncology platform
- Lucid Diagnostics
Non-endoscopic molecular testing for Barrett’s esophagus and precancer
- NeoGenomics
Oncology molecular testing with ctDNA monitoring for high-risk melanoma
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Castle Biosciences | $33.50 | +0.18% | $1.02B | — | — | 2.9 | +20.1% |
| Quest Diagnostics | $244.50 | +0.69% | $26.79B | 25.8 | 21.2 | 2.3 | +10.2% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Lucid Diagnostics | $1.00 | +0.36% | $189.1M | — | — | 34.7 | +26.7% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Median | 25.8 | 43.1 | 5.1 | +16.4% |